References analysis of the Wikipedia article "Multipla skleroza" in the Serbian version

doi.org

Compston A, Coles A (2008). „Multiple sclerosis”. Lancet. 372 (9648): 1502—17. PMID 18970977. S2CID 195686659. doi:10.1016/S0140-6736(08)61620-7.

Rosati, G (2001). „The prevalence of multiple sclerosis in the world: an update”. Neurol. Sci. 22 (2): 117—39. PMID 11603614. doi:10.1007/s100720170011.

Pearce (2005). „Historical descriptions of multiple sclerosis.”. Eur Neurol. 54 (1): 49—53. PMID 16103678. S2CID 43674024. doi:10.1159/000087387.

McDonald, W. I. (1999). „Physicians, subsequence and consequence”. Journal of Neurology, Neurosurgery, and Psychiatry. 67 (3): 282—9. PMC 1736520 

. PMID 10449547. doi:10.1136/jnnp.67.3.282.

Alonso, A.; Hernán, M. A. (2008). „Temporal trends in the incidence of multiple sclerosis: A systematic review”. Neurology. 71 (2): 129—135. PMC 4109189 

. PMID 18606967. doi:10.1212/01.wnl.0000316802.35974.34. .

Kurtzke JF (1993). „Epidemiologic evidence for multiple sclerosis as an infection”. Clin. Microbiol. Rev. 6 (4): 382—427. PMC 358295 

. PMID 8269393. doi:10.1128/CMR.6.4.382.

Marrosu, M. G. (2007). „Susceptibility to multiple sclerosis: The role of interleukin genes”. Lancet Neurol. 6 (10): 846—7. PMID 17884670. S2CID 11253769. doi:10.1016/S1474-4422(07)70228-4.

Hein, T.; Hopfenmüller, W. (2000). „Projection of the number of multiple sclerosis patients in Germany”. Nervenarzt. 71 (4): 288—94. PMID 10795096. S2CID 19429191. doi:10.1007/s001150050559..

Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). „Vitamin D: an evidence-based review”. J Am Board Fam Med. 22 (6): 698—706. PMID 19897699. S2CID 15878521. doi:10.3122/jabfm.2009.06.090037.

Poser, S.; Poser, W.; Schlaf, G.; Firnhaber, W.; Lauer, K.; Wolter, M.; Evers, P. (1986). „Prognostic indicators in multiple sclerosis”. Acta Neurol Scand. 74 (5): 387—92. PMID 3825497. S2CID 42211498. doi:10.1111/j.1600-0404.1986.tb03531.x.

Sadovnick, A. D.; Ebers, G. C.; Wilson, R. W.; Paty, D. W. (1992). „Life expectancy in patients attending multiple sclerosis clinics”. Neurology. 42 (5): 991—4. PMID 1579256. S2CID 34410395. doi:10.1212/WNL.42.5.991..

Marrie RA (децембар 2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol. 3 (12): 709—18. PMID 15556803. S2CID 175786. doi:10.1016/S1474-4422(04)00933-0.

McElroy, J. P.; Oksenberg, J. R. (2011). „Multiple sclerosis genetics 2010”. Neurol Clin. 29 (2): 219—31. PMID 21439438. doi:10.1016/j.ncl.2010.12.002..

Ascherio A, Munger KL (2007). „Environmental risk factors for multiple sclerosis. Part I: the role of infection”. Ann. Neurol. (на језику: енглески). 61 (4): 288—99. PMID 17444504. S2CID 7682774. doi:10.1002/ana.21117.

Marrie, RA (2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol}-. 3 (12): 709—18. PMID 15556803. S2CID 175786. doi:10.1016/S1474-4422(04)00933-0.

Ascherio A, Munger KL (2007). „Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors”. Ann. Neurol.. 61 (6): 504—13. PMID 17492755. S2CID 36999504. doi:10.1002/ana.21141.

Dyment DA, Ebers GC, Sadovnick AD (2004). „Genetics of multiple sclerosis”. Lancet Neurol. 3 (92): 104—10. PMID 14747002. S2CID 16707321. doi:10.1016/S1474-4422(03)00663-X.

Orton, S. M.; Herrera, B. M.; Yee, I. M.; Valdar, W.; Ramagopalan, S. V.; Sadovnick, A. D.; Ebers, G. C.; Canadian Collaborative Study Group (2006). „Sex ratio of multiple sclerosis in Canada: A longitudinal study”. Lancet Neurol. 5 (11): 932—6. PMID 17052660. S2CID 6988114. doi:10.1016/S1474-4422(06)70581-6.

Compston A, Coles A (2002). „Multiple sclerosis”. Lancet. 359 (9313): 1221—31. PMID 11955556. S2CID 14207583. doi:10.1016/S0140-6736(02)08220-X.

De Jager, P. L.; Chibnik, L. B.; Cui, J.; Reischl, J.; Lehr, S.; Simon, K. C.; Aubin, C.; Bauer, D.; Heubach, J. F.; Sandbrink, R.; Tyblova, M.; Lelkova, P.; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study; Havrdova, E.; Pohl, C.; Horakova, D.; Ascherio, A.; Hafler, D. A.; Karlson, E. W. (2009). „Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score”. Lancet Neurol. 8 (12): 1111—9. PMC 3099419 

. PMID 19879194. doi:10.1016/S1474-4422(09)70275-3..

Gilden, DH (2005). „Infectious causes of multiple sclerosis ”. The Lancet Neurology. 4 (3): 195—202. PMC 7129502 

. PMID 15721830. doi:10.1016/S1474-4422(05)01017-3.

Alotaibi; et al. (2004). „Epstein-Barr virus in pediatric multiple sclerosis.”. JAMA. 291 (15): 1875—9. PMID 15100207. doi:10.1001/jama.291.15.1875.

Sotelo, J.; et al. (2008). „Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis”. Ann. Neurol. (на језику: (језик: енглески)). 63 (3): 303—311. PMID 18306233. S2CID 36489072. doi:10.1002/ana.21316.

Lunemann, JD.; et al. (2007). „Epstein-barr virus: environmental trigger of multiple sclerosis?”. J. Virol. (на језику: енглески). 81 (13): 6777—84. PMC 1933281 

. PMID 17459939. doi:10.1128/JVI.00153-07.

Farrell, RA.; et al. (2009). „Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI”. Neurology (на језику: енглески). 73 (1): 32—38. PMC 2848585 

. PMID 19458321. doi:10.1212/WNL.0b013e3181aa29fe.

Johnston, JB.; et al. (2001). „Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases”. Ann. Neurol. (на језику: енглески). 50 (4): 434—42. PMID 11601494. S2CID 25171437. doi:10.1002/ana.1131.

Yao, SY.; et al. (2001). „CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens”. Neurology (на језику: енглески). 56 (9): 1168—76. PMID 11342681. S2CID 26566019. doi:10.1212/wnl.56.9.1168.

Levin, L. I.; Munger, K. L.; Rubertone, M. V.; Peck, C. A.; Lennette, E. T.; Spiegelman, D.; Ascherio, A. (2003). „Multiple sclerosis and Epstein-Barr virus”. JAMA. 289 (12): 1533—6. PMID 12672770. doi:10.1001/jama.289.12.1533.

Levin, L. I.; Munger, K. L.; O'Reilly, E. J.; Falk, K. I.; Ascherio, A. (2010). „Primary infection with the Epstein-Barr virus and risk of multiple sclerosis”. Ann Neurol. 67 (6): 824—30. PMC 3089959 

. PMID 20517945. doi:10.1002/ana.21978..

Ascherio A, Munger KL (2010). „Epstein-barr virus infection and multiple sclerosis: a review”. J Neuroimmune Pharmacol. 5 (3): 271—7. PMID 20369303. S2CID 24409610. doi:10.1007/s11481-010-9201-3..

Cepok, S.; Zhou, D.; Srivastava, R.; Nessler, S.; Stei, S.; Büssow, K.; Sommer, N.; Hemmer, B. (2005). „Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis”. J Clin Invest. 115 (5): 1352—60. PMC 1077174 

. PMID 15841210. doi:10.1172/JCI200523661..

Lang, H. L.; Jacobsen, H.; Ikemizu, S.; Andersson, C.; Harlos, K.; Madsen, L.; Hjorth, P.; Sondergaard, L.; Svejgaard, A.; Wucherpfennig, K.; Stuart, D. I.; Bell, J. I.; Jones, E. Y.; Fugger, L. (2002). „A functional and structural basis for TCR cross-reactivity in multiple sclerosis”. Nat Immunol. 3 (10): 940—3. PMID 12244309. S2CID 35781758. doi:10.1038/ni835..

Serafini, B.; Rosicarelli, B.; Franciotta, D.; Magliozzi, R.; Reynolds, R.; Cinque, P.; Andreoni, L.; Trivedi, P.; Salvetti, M.; Faggioni, A.; Aloisi, F. (2007). „Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain”. J Exp Med. 204 (12): 2899—912. PMC 2118531 

. PMID 17984305. doi:10.1084/jem.20071030..

Mikaeloff, Y.; Caridade, G.; Tardieu, M.; Suissa, S.; KIDSEP study group (2007). „Parental smoking at home and the risk of childhood-onset multiple sclerosis in children”. Brain. 130 (Pt 10): 2589—95. PMID 17827175. doi:10.1093/brain/awm198..

Hernán, M. A.; Jick, S. S.; Logroscino, G.; Olek, M. J.; Ascherio, A.; Jick, H. (2005). „Cigarette smoking and the progression of multiple sclerosis”. Brain. 128 (Pt 6): 1461—5. PMID 15758034. doi:10.1093/brain/awh471..

Hulter, B. M.; Lundberg, P. O. (јул 1995). „Sexual function in women with advanced multiple sclerosis”. Journal of Neurology, Neurosurgery, and Psychiatry. 59 (1): 83—6. PMC 1073606 

. PMID 7608715. doi:10.1136/jnnp.59.1.83.

Zorzon, M.; Zivadinov, R.; Bosco, A.; Bragadin, L. M.; Moretti, R.; Bonfigli, L.; Morassi, P.; Iona, L. G.; Cazzato, G. (1999). „Sexual dysfunction in multiple sclerosis: A case-control study. I. Frequency and comparison of groups”. Multiple Sclerosis (Houndmills, Basingstoke, England). 5 (6): 418—427. PMID 10618699. S2CID 36845693. doi:10.1177/135245859900500i609.

Borello-France, D.; Leng, W.; O'Leary, M.; Xavier, M.; Erickson, J.; Chancellor, M. B.; Cannon, T. W. (август 2004). „Bladder and sexual function among women with multiple sclerosis”. Multiple Sclerosis (Houndmills, Basingstoke, England). 10 (4): 455—61. PMID 15327046. S2CID 23714985. doi:10.1191/1352458504ms1060oa.

Dasgupta, R.; Fowler, C. J. (2002). „Sexual and urological dysfunction in multiple sclerosis: Better understanding and improved therapies”. Current Opinion in Neurology. 15 (3): 271—278. PMID 12045724. S2CID 43751384. doi:10.1097/00019052-200206000-00008.

Nelson, F.; Poonawalla, A. H.; Hou, P.; Huang, F.; Wolinsky, J. S.; Narayana, P. A. (октобар 2007). „Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging”. AJNR Am J Neuroradiol. 28 (9): 1645—9. PMC 8134176 

. PMID 17885241. doi:10.3174/ajnr.A0645. Пронађени су сувишни параметри: author-name-list parameters (помоћ)

Nelson F; Poonawalla A; Hou P; Wolinsky JS; Narayana PA (новембар 2008). „3D MPRAGE improves classification of cortical lesions in multiple sclerosis”. Mult Scler. 14 (9): 1214—9. PMC 2650249 

. PMID 18952832. doi:10.1177/1352458508094644.

Roos, K. L. (2003). „Lumbar Puncture”. Seminars in Neurology. 23 (1): 105—114. PMID 12870112. S2CID 41878896. doi:10.1055/s-2003-40758.

Farley, A.; McLafferty, E. (2008). „Lumbar puncture”. Nurs Stand. 22 (22): 46—8. PMID 18333557. doi:10.7748/ns2008.02.22.22.46.c6358..

Petzold, A.; Brettschneider, J.; Jin, K.; Keir, G.; Murray, N. M.; Hirsch, N. P.; Itoyama, Y.; Reilly, M. M.; Takeda, A.; Tumani, H. (јул 2009). „CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome”. Muscle Nerve. 40 (1): 42—9. PMID 19533642. S2CID 25304503. doi:10.1002/mus.21239..

Kurtzke, J. F. (1983). „Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)”. Neurology. 33 (11): 1444—1452. PMID 6685237. S2CID 34222883. doi:10.1212/wnl.33.11.1444.

Rolak, L. A.; Fleming, J. O. (2007). „The differential diagnosis of multiple sclerosis”. The Neurologist. 13 (2): 57—72. PMID 17351525. S2CID 13729395. doi:10.1097/01.nrl.0000254705.39956.34.

Thompson, A. J.; Polman, C. H.; Miller, D. H.; McDonald, W. I.; Brochet, B.; Filippi m Montalban, X.; De Sá, J. (1997). Primary progressive multiple sclerosis. Brain : A Journal of Neurology. 120 ( Pt 6). стр. 1085—1096. PMID 9217691. doi:10.1093/brain/120.6.1085.

Confavreux, C. (2002). Infections and the risk of relapse in multiple sclerosis. Brain : A Journal of Neurology. 125. стр. 933—934. PMID 11960883. doi:10.1093/brain/awf146.

Filippini, G.; Munari, L.; Incorvaia, B.; Ebers, G. C.; Polman, C.; d'Amico, R.; Rice, G. P. (2003). „Interferons in relapsing remitting multiple sclerosis: A systematic review”. Lancet (London, England). 361 (9357): 545—52. PMID 12598138. S2CID 16141234. doi:10.1016/S0140-6736(03)12512-3.

Galetta, SL (2001). „The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study)”. J Neuroophthalmol. 21 (4): 292—5. PMID 11756862. S2CID 9467518. doi:10.1097/00041327-200112000-00013.

Munari, L.; Lovati, R.; Boiko, A. (2004). Munari, Luca M., ур. „Therapy with glatiramer acetate for multiple sclerosis”. The Cochrane Database of Systematic Reviews (1): CD004678. PMID 14974077. doi:10.1002/14651858.CD004678.

Casetta, I.; Iuliano, G.; Filippini, G. (2007). „Azathioprine for multiple sclerosis”. The Cochrane Database of Systematic Reviews. 2007 (4): CD003982. PMC 6823213 

. PMID 17943809. doi:10.1002/14651858.CD003982.pub2.

Gray, O.; McDonnell, G. V.; Forbes, R. B. (2003). „Intravenous immunoglobulins for multiple sclerosis”. The Cochrane Database of Systematic Reviews. 2003 (4): CD002936. PMC 8407393 

. PMID 14583956. doi:10.1002/14651858.CD002936.

Polman; et al. (2006). „A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.”. New England Journal of Medicine. 354 (9): 899—910. PMID 16510744. doi:10.1056/NEJMoa044397.

Martinelli Boneschi, F.; Rovaris, M.; Capra, R.; Comi, G. (2005). Martinelli Boneschi, Filippo, ур. „Mitoxantrone for multiple sclerosis”. The Cochrane Database of Systematic Reviews (4): CD002127. PMID 16235298. doi:10.1002/14651858.CD002127.pub2.

La Mantia, L.; Milanese, C.; Mascoli, N.; d'Amico, R.; Weinstock-Guttman, B. (2007). „Cyclophosphamide for multiple sclerosis”. The Cochrane Database of Systematic Reviews. 2007 (1): CD002819. PMC 8078225 

. PMID 17253481. doi:10.1002/14651858.CD002819.pub2.

Rudge, P; Koetsier, JC; Mertin, J; Mispelblom B.J.O.; HK, Van Walbeek; Jones, RC; Harrison, J; Robinson, K; Mellein, B; Poole T (1989). „Randomised double blind controlled trial of cyclosporin in multiple sclerosis”. J Neurol Neurosurg Psychiatry. 52 (5): 559—565. PMC 1032160 

. PMID 2659736. doi:10.1136/jnnp.52.5.559.

Gray O, McDonnell GV, Forbes RB (2004). „Methotrexate for multiple sclerosis”. Cochrane Reviews. 2010 (10): CD003208. PMC 9006525 

. PMID 15106195. doi:10.1002/14651858.CD003208.pub2.

La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V (1994). „Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses”. Eur Neurol. 34 (4): 199—203. PMID 7915989. doi:10.1159/000117038.

Schmelzeisen R, Frölich JC (2004). „Prevention of postoperative swelling and pain by dexamethasone after operative removal of impacted third molar teeth”. European Journal of Clinical Pharmacology. 44 (3): 275—277. PMID 8491244. S2CID 12528750. doi:10.1007/BF00271371.

Diabetic Retinopathy Clinical Research Network (2008). „A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema”. Ophthalmology. 115 (9): 1447—9. PMC 2748264 

. PMID 18662829. doi:10.1016/j.ophtha.2008.06.015.

Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA (2005). „Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial”. Invest Ophthalmol Vis Sci. 46 (10): 3845—9. PMID 16186372. doi:10.1167/iovs.05-0297.

Lukas, Carsten; Bellenberg, Barbara; Hahn, Horst K.; Rexilius, Jan; Drescher, Robert; Hellwig, Kerstin; Köster, Odo; Schimrigk, Sebastian (2009). „Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy”. Ther Adv Neurol Disorders. 2 (6): 349—355. PMC 3002603 

. PMID 21180629. doi:10.1177/1756285609343480.

Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T (2003). „Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients”. J Neurol Sci. 211 (1): 81—4. PMID 12767502. S2CID 1571002. doi:10.1016/s0022-510x(03)00060-1.

Magne D, Mézin F, Palmer G, Guerne PA (2006). „The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha”. Inflamm. Res. 55 (11): 469—75. PMID 17122964. S2CID 49690. doi:10.1007/s00011-006-5196-x.

Cohen, JA (2009). „Emerging therapies for relapsing multiple sclerosis”. Arch. Neurol. 66 (7): 821—8. PMID 19597083. doi:10.1001/archneurol.2009.104.

Havrdova, E.; Horakova, D.; Kovarova, I. (2015). „Use for MS”. Therapeutic Advances in Neurological Disorders. 8 (1): 31—45. PMC 4286943 

. PMID 25584072. doi:10.1177/1756285614563522.

Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG (2007). „Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results”. Neurology. 69 (8): 785—789. PMID 17709711. S2CID 35384444. doi:10.1212/01.wnl.0000267662.41734.1f.

Warren, K. G.; Catz, I.; Ferenczi, L. Z.; Krantz, M. J. (2006). „Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: Results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment”. European Journal of Neurology. 13 (8): 887—895. PMID 16879301. S2CID 8390406. doi:10.1111/j.1468-1331.2006.01533.x.

„Giovannoni G, et al., NEJM 2010”. doi:10.1056/NEJMoa0902533.

Kappos, L; et al. (2010). „A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis”. New England Journal of Medicine. 362 (5): 387—401. PMID 20089952. doi:10.1056/NEJMoa0909494.

Tan, IL; à, Lycklama; Nijeholt, GJ; Polman, CH; et al. (2000). „Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials”. Mult Scler. 6 (2): 99—104. PMID 10773855. S2CID 31171852. doi:10.1177/135245850000600208.

Comi, G; Pulizzi, A; Rovaris, M; et al. (2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet. 371 (9630): 2085—92. PMID 18572078. S2CID 26606958. doi:10.1016/S0140-6736(08)60918-6.

Polman, C; Barkhof, F; Sandberg-Wollheim M; et al. (2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology. 64 (6): 987—91. PMID 15781813. S2CID 17295219. doi:10.1212/01.WNL.0000154520.48391.69.

Keegan BM, Weinshenker BG (2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet. 371 (9630): 2059—60. PMID 18572062. S2CID 205951331. doi:10.1016/S0140-6736(08)60894-6.

Burton JM, O'Connor PW, Hohol M, Beyene J (2009). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". Cochrane Database Syst Rev (3): CD006921. Burton, Jodie M.; O'Connor, Paul W.; Hohol, Marika; Beyene, Joseph (2009). „Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis”. Ур.: Burton, Jodie M. Cochrane Database of Systematic Reviews. стр. CD006921. PMID 19588409. doi:10.1002/14651858.CD006921.pub2.

Comi, G; et al. (2009). „Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial”. Lancet. 374 (9700): 1503—11. PMID 19815268. S2CID 32012123. doi:10.1016/S0140-6736(09)61259-9. Непознати параметар |name-list-style= игнорисан (помоћ)

Johnson, KP (2010). „Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis”. Ther Clin Risk Manag. Volume=15. 6 (6): 153—72. PMC 2857614 

. PMID 20421914. doi:10.2147/tcrm.s6743.

Rietberg; et al. (2005). „Exercise therapy for multiple sclerosis.”. Cochrane Database Syst Rev. 2005; CD003980. 2005 (1): CD003980. PMC 6485797 

. PMID 15674920. doi:10.1002/14651858.CD003980.pub2. (Meta-Analyse)

Kesselring, J.; Beer, S. (2005). „Symptomatic therapy and neurorehabilitation in multiple sclerosis”. The Lancet. Neurology. 4 (10): 643—652. PMID 16168933. S2CID 28253186. doi:10.1016/S1474-4422(05)70193-9.

Pittock, S. J.; Mayr, W. T.; McClelland, R. L.; Jorgensen, N. W.; Weigand, S. D.; Noseworthy, J. H.; Weinshenker, B. G.; Rodriguez, M. (2004). „Change in MS-related disability in a population-based cohort: A 10-year follow-up study”. Neurology. 62 (1): 51—59. PMID 14718697. S2CID 21814813. doi:10.1212/01.wnl.0000101724.93433.00.

Daumer, M.; Neuhaus, A.; Lederer, C.; Scholz, M.; Wolinsky, J. S.; Heiderhoff, M.; Sylvia Lawry Centre for Multiple Sclerosis Research (2007). „Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis”. BMC Medical Informatics and Decision Making. 7: 11. PMC 1884137 

. PMID 17488517. doi:10.1186/1472-6947-7-11.

Weinshenker, BG (1994). „Natural history of multiple sclerosis”. Ann. Neurol. 36 (Suppl): S6—11. PMID 8017890. S2CID 7140070. doi:10.1002/ana.410360704.

Compston A, Coles A (2008). „Multiple sclerosis”. Lancet. 372 (9648): 1502—17. PMID 18970977. S2CID 195686659. doi:10.1016/S0140-6736(08)61620-7.

Myhr, KM; Riise, T; Vedeler, C; et al. (2001). „Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension”. Mult. Scler. 7 (1): 59—65. PMID 11321195. S2CID 5769159. doi:10.1177/135245850100700110.

Vedantham, S; Benenati, JF; Kundu, S; Black, CM; Murphy, KJ; Cardella, JF (2010). „Interventional endovascular management of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a position statement by the Society of Interventional Radiology, endorsed by the Canadian Interventional Radiology Association.”. Journal of Vascular and Interventional Radiology : JVIR. 21 (9): 1335—7. PMID 20800776. doi:10.1016/j.jvir.2010.07.004.

Zamboni, P.; Menegatti, E.; Weinstock-Guttman, B.; Dwyer, M. G.; Schirda, C. V.; Malagoni, A. M.; Hojnacki, D.; Kennedy, C.; Carl, E.; Bergsland, N.; Magnano, C.; Bartolomei, I.; Salvi, F.; Zivadinov, R. (март 2011). „Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: A cross-sectional preliminary report”. BMC Med. 9 (1): 22. PMC 3059278 

. PMID 21385345. doi:10.1186/1741-7015-9-22 

Tremlett, H.; Zhao, Y.; Rieckmann, P.; Hutchinson, M. (2010). „New perspectives in the natural history of multiple sclerosis”. Neurology. 74 (24): 2004—2015. PMID 20548045. S2CID 6569915. doi:10.1212/WNL.0b013e3181e3973f.

Zamboni, P.; Galeotti, R.; Menegatti, E.; Malagoni, A. M.; Tacconi, G.; Dall'Ara, S.; Bartolomei, I.; Salvi, F. (2009). „Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis”. J Neurol Neurosurg Psychiatry. 80 (4): 392—399. PMC 2647682 

. PMID 19060024. doi:10.1136/jnnp.2008.157164.

Singh, A. V.; Zamboni, P. (2009). „Anomalous venous blood flow and iron deposition in multiple sclerosis”. J Cereb Blood Flow Metab. 29 (12): 1867—1878. PMID 19724286. S2CID 1809822. doi:10.1038/jcbfm.2009.180.

Zamboni, P.; Galeotti, R.; Menegatti, E.; Malagoni, A. M.; Gianesini, S.; Bartolomei, I.; Mascoli, F.; Salvi, F. (2009). „A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency”. J Vasc Surg. 50 (6): 1348—1358. PMID 19958985. doi:10.1016/j.jvs.2009.07.096.

Hirtz, D.; Thurman, D. J.; Gwinn-Hardy, K.; Mohamed, M.; Chaudhuri, A. R.; Zalutsky, R. (2007). „How common are the "common" neurologic disorders?”. Neurology. 68 (5): 326—337. PMID 17261678. S2CID 15955578. doi:10.1212/01.wnl.0000252807.38124.a3.

Mayr, W. T.; Pittock, S. J.; McClelland, R. L.; Jorgensen, N. W.; Noseworthy, J. H.; Rodriguez, M. (2003). „Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000”. Neurology. 61 (10): 1373—1377. PMID 14638958. S2CID 2479864. doi:10.1212/01.WNL.0000094316.90240.EB.

Zamboni, P.; Galeotti, R.; Menegatti, E.; Malagoni, A. M.; Tacconi, G.; Dall'Ara, S.; Bartolomei, I.; Salvi, F. (2008). „Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis”. Journal of Neurology, Neurosurgery & Psychiatry. 80 (4): 392——. PMC 2647682 

. PMID 19060024. doi:10.1136/jnnp.2008.157164..

nih.gov

ncbi.nlm.nih.gov

Compston A, Coles A (2008). „Multiple sclerosis”. Lancet. 372 (9648): 1502—17. PMID 18970977. S2CID 195686659. doi:10.1016/S0140-6736(08)61620-7.

Rosati, G (2001). „The prevalence of multiple sclerosis in the world: an update”. Neurol. Sci. 22 (2): 117—39. PMID 11603614. doi:10.1007/s100720170011.

Pearce (2005). „Historical descriptions of multiple sclerosis.”. Eur Neurol. 54 (1): 49—53. PMID 16103678. S2CID 43674024. doi:10.1159/000087387.

McDonald, W. I. (1999). „Physicians, subsequence and consequence”. Journal of Neurology, Neurosurgery, and Psychiatry. 67 (3): 282—9. PMC 1736520 

. PMID 10449547. doi:10.1136/jnnp.67.3.282.

Alonso, A.; Hernán, M. A. (2008). „Temporal trends in the incidence of multiple sclerosis: A systematic review”. Neurology. 71 (2): 129—135. PMC 4109189 

. PMID 18606967. doi:10.1212/01.wnl.0000316802.35974.34. .

Kurtzke JF (1993). „Epidemiologic evidence for multiple sclerosis as an infection”. Clin. Microbiol. Rev. 6 (4): 382—427. PMC 358295 

. PMID 8269393. doi:10.1128/CMR.6.4.382.

Marrosu, M. G. (2007). „Susceptibility to multiple sclerosis: The role of interleukin genes”. Lancet Neurol. 6 (10): 846—7. PMID 17884670. S2CID 11253769. doi:10.1016/S1474-4422(07)70228-4.

Marrie RA (децембар 2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol. 3 (12): 709—18. PMID 15556803. S2CID 175786. doi:10.1016/S1474-4422(04)00933-0.

McElroy, J. P.; Oksenberg, J. R. (2011). „Multiple sclerosis genetics 2010”. Neurol Clin. 29 (2): 219—31. PMID 21439438. doi:10.1016/j.ncl.2010.12.002..

Marrie, RA (2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol}-. 3 (12): 709—18. PMID 15556803. S2CID 175786. doi:10.1016/S1474-4422(04)00933-0.

Dyment DA, Ebers GC, Sadovnick AD (2004). „Genetics of multiple sclerosis”. Lancet Neurol. 3 (92): 104—10. PMID 14747002. S2CID 16707321. doi:10.1016/S1474-4422(03)00663-X.

Compston A, Coles A (2002). „Multiple sclerosis”. Lancet. 359 (9313): 1221—31. PMID 11955556. S2CID 14207583. doi:10.1016/S0140-6736(02)08220-X.

. PMID 19879194. doi:10.1016/S1474-4422(09)70275-3..

Gilden, DH (2005). „Infectious causes of multiple sclerosis ”. The Lancet Neurology. 4 (3): 195—202. PMC 7129502 

. PMID 15721830. doi:10.1016/S1474-4422(05)01017-3.

Alotaibi; et al. (2004). „Epstein-Barr virus in pediatric multiple sclerosis.”. JAMA. 291 (15): 1875—9. PMID 15100207. doi:10.1001/jama.291.15.1875.

Lunemann, JD.; et al. (2007). „Epstein-barr virus: environmental trigger of multiple sclerosis?”. J. Virol. (на језику: енглески). 81 (13): 6777—84. PMC 1933281 

. PMID 17459939. doi:10.1128/JVI.00153-07.

. PMID 19458321. doi:10.1212/WNL.0b013e3181aa29fe.

Christensen, T (2006). „The role of EBV in MS pathogenesis”. Int MS J (на језику: енглески). 13 (2): 52—7. PMID 16635422.

. PMID 20517945. doi:10.1002/ana.21978..

. PMID 15841210. doi:10.1172/JCI200523661..

. PMID 17984305. doi:10.1084/jem.20071030..

Hulter, B. M.; Lundberg, P. O. (јул 1995). „Sexual function in women with advanced multiple sclerosis”. Journal of Neurology, Neurosurgery, and Psychiatry. 59 (1): 83—6. PMC 1073606 

. PMID 7608715. doi:10.1136/jnnp.59.1.83.

. PMID 17885241. doi:10.3174/ajnr.A0645. Пронађени су сувишни параметри: author-name-list parameters (помоћ)

. PMID 18952832. doi:10.1177/1352458508094644.

Wattjes, M. P.; Lutterbey, G. G.; Gieseke, J.; Träber, F.; Klotz, L.; Schmidt, S.; Schild, H. H. (2007). „Double inversion recovery brain imaging at 3T: Diagnostic value in the detection of multiple sclerosis lesions”. AJNR. American Journal of Neuroradiology. 28 (1): 54—59. PMC 8134107 

. PMID 17213424.

Roos, K. L. (2003). „Lumbar Puncture”. Seminars in Neurology. 23 (1): 105—114. PMID 12870112. S2CID 41878896. doi:10.1055/s-2003-40758.

Farley, A.; McLafferty, E. (2008). „Lumbar puncture”. Nurs Stand. 22 (22): 46—8. PMID 18333557. doi:10.7748/ns2008.02.22.22.46.c6358..

Rolak, L. A.; Fleming, J. O. (2007). „The differential diagnosis of multiple sclerosis”. The Neurologist. 13 (2): 57—72. PMID 17351525. S2CID 13729395. doi:10.1097/01.nrl.0000254705.39956.34.

Confavreux, C. (2002). Infections and the risk of relapse in multiple sclerosis. Brain : A Journal of Neurology. 125. стр. 933—934. PMID 11960883. doi:10.1093/brain/awf146.

Casetta, I.; Iuliano, G.; Filippini, G. (2007). „Azathioprine for multiple sclerosis”. The Cochrane Database of Systematic Reviews. 2007 (4): CD003982. PMC 6823213 

. PMID 17943809. doi:10.1002/14651858.CD003982.pub2.

Gray, O.; McDonnell, G. V.; Forbes, R. B. (2003). „Intravenous immunoglobulins for multiple sclerosis”. The Cochrane Database of Systematic Reviews. 2003 (4): CD002936. PMC 8407393 

. PMID 14583956. doi:10.1002/14651858.CD002936.

. PMID 17253481. doi:10.1002/14651858.CD002819.pub2.

. PMID 2659736. doi:10.1136/jnnp.52.5.559.

Gray O, McDonnell GV, Forbes RB (2004). „Methotrexate for multiple sclerosis”. Cochrane Reviews. 2010 (10): CD003208. PMC 9006525 

. PMID 15106195. doi:10.1002/14651858.CD003208.pub2.

. PMID 18662829. doi:10.1016/j.ophtha.2008.06.015.

. PMID 21180629. doi:10.1177/1756285609343480.

Cohen, JA (2009). „Emerging therapies for relapsing multiple sclerosis”. Arch. Neurol. 66 (7): 821—8. PMID 19597083. doi:10.1001/archneurol.2009.104.

Havrdova, E.; Horakova, D.; Kovarova, I. (2015). „Use for MS”. Therapeutic Advances in Neurological Disorders. 8 (1): 31—45. PMC 4286943 

. PMID 25584072. doi:10.1177/1756285614563522.

Keegan BM, Weinshenker BG (2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet. 371 (9630): 2059—60. PMID 18572062. S2CID 205951331. doi:10.1016/S0140-6736(08)60894-6.

. PMID 20421914. doi:10.2147/tcrm.s6743.

Rietberg; et al. (2005). „Exercise therapy for multiple sclerosis.”. Cochrane Database Syst Rev. 2005; CD003980. 2005 (1): CD003980. PMC 6485797 

. PMID 15674920. doi:10.1002/14651858.CD003980.pub2. (Meta-Analyse)

. PMID 17488517. doi:10.1186/1472-6947-7-11.

Weinshenker, BG (1994). „Natural history of multiple sclerosis”. Ann. Neurol. 36 (Suppl): S6—11. PMID 8017890. S2CID 7140070. doi:10.1002/ana.410360704.

Compston A, Coles A (2008). „Multiple sclerosis”. Lancet. 372 (9648): 1502—17. PMID 18970977. S2CID 195686659. doi:10.1016/S0140-6736(08)61620-7.

. PMID 21385345. doi:10.1186/1741-7015-9-22 

. PMID 19060024. doi:10.1136/jnnp.2008.157164.

Embry, A. F. (2010). „Integrating CCSVI and CNS autoimmunity in a disease model for MS”. Int Angiol. 29 (2): 93—94. PMID 20351664.

Zamboni, P.; Menegatti, E.; Weinstock-Guttman, B.; Schirda, C.; Cox, J. L.; Malagoni, A. M.; Hojnacki, D.; Kennedy, C.; Carl, E.; Dwyer, M. G.; Bergsland, N.; Galeotti, R.; Hussein, S.; Bartolomei, I.; Salvi, F.; Ramanathan, M.; Zivadinov, R. (2010). „CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: A pilot study”. Int Angiol. 29 (2): 140—148. PMID 20351670.

Al-Omari MH, Rousan LA. Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. Int Angiol. 29: 115—120. 2010. PMID 20351667. Недостаје или је празан параметар |title= (помоћ)

Simka, M.; Kostecki, J.; Zaniewski, M.; Majewski, E.; Hartel, M. (2010). „Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis”. Int Angiol. 29 (2): 109—114. PMID 20351666.

Malagoni, A. M.; Galeotti, R.; Menegatti, E.; Manfredini, F.; Basaglia, N.; Salvi, F.; Zamboni, P. (2010). „Is chronic fatigue the symptom of venous insufficiency associated with multiple sclerosis? A longitudinal pilot study”. Int Angiol. 29 (2): 176—182. PMID 20351673.

. PMID 19060024. doi:10.1136/jnnp.2008.157164..

semanticscholar.org

api.semanticscholar.org

Compston A, Coles A (2008). „Multiple sclerosis”. Lancet. 372 (9648): 1502—17. PMID 18970977. S2CID 195686659. doi:10.1016/S0140-6736(08)61620-7.

Pearce (2005). „Historical descriptions of multiple sclerosis.”. Eur Neurol. 54 (1): 49—53. PMID 16103678. S2CID 43674024. doi:10.1159/000087387.

Marrosu, M. G. (2007). „Susceptibility to multiple sclerosis: The role of interleukin genes”. Lancet Neurol. 6 (10): 846—7. PMID 17884670. S2CID 11253769. doi:10.1016/S1474-4422(07)70228-4.

Marrie RA (децембар 2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol. 3 (12): 709—18. PMID 15556803. S2CID 175786. doi:10.1016/S1474-4422(04)00933-0.

Marrie, RA (2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol}-. 3 (12): 709—18. PMID 15556803. S2CID 175786. doi:10.1016/S1474-4422(04)00933-0.

Dyment DA, Ebers GC, Sadovnick AD (2004). „Genetics of multiple sclerosis”. Lancet Neurol. 3 (92): 104—10. PMID 14747002. S2CID 16707321. doi:10.1016/S1474-4422(03)00663-X.

Compston A, Coles A (2002). „Multiple sclerosis”. Lancet. 359 (9313): 1221—31. PMID 11955556. S2CID 14207583. doi:10.1016/S0140-6736(02)08220-X.

Roos, K. L. (2003). „Lumbar Puncture”. Seminars in Neurology. 23 (1): 105—114. PMID 12870112. S2CID 41878896. doi:10.1055/s-2003-40758.

Rolak, L. A.; Fleming, J. O. (2007). „The differential diagnosis of multiple sclerosis”. The Neurologist. 13 (2): 57—72. PMID 17351525. S2CID 13729395. doi:10.1097/01.nrl.0000254705.39956.34.

Keegan BM, Weinshenker BG (2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet. 371 (9630): 2059—60. PMID 18572062. S2CID 205951331. doi:10.1016/S0140-6736(08)60894-6.

Weinshenker, BG (1994). „Natural history of multiple sclerosis”. Ann. Neurol. 36 (Suppl): S6—11. PMID 8017890. S2CID 7140070. doi:10.1002/ana.410360704.

Compston A, Coles A (2008). „Multiple sclerosis”. Lancet. 372 (9648): 1502—17. PMID 18970977. S2CID 195686659. doi:10.1016/S0140-6736(08)61620-7.

Multipla skleroza (Serbian Wikipedia)

aerzteblatt.de

archive.org

clinicaltrials.gov

dmsbpz.hr

doi.org

drugs.com

fda.gov

accessdata.fda.gov

karnopedia.com

mayoclinic.org

newsnetwork.mayoclinic.org

medicalnewstoday.com

medscape.com

emedicine.medscape.com

ms-info.net

msrc.co.uk

mult-sclerosis.org

mymsaa.org

nejm.org

content.nejm.org

nih.gov

ncbi.nlm.nih.gov

reuters.com

sagepub.com

journals.sagepub.com

semanticscholar.org

api.semanticscholar.org

stetoskop.info

web.archive.org

webmd.com

weizmann.ac.il